Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100984 · ClinicalTrials.gov registry record · Phase 4
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT00100984: Clinical Trial Phase 4 study, sponsored by Hoffmann-La Roche.
NCT00100984 is a Phase 4 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 8 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00100984, a Phase 4 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.
Interventions
- DRUG FUZEON [enfuvirtide]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-07-21 |
| Est. Completion | 2005-07-16 |
| Phase | Phase 4 |
Why NCT00100984 stopped before completion
NCT00100984 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which FUZEON [enfuvirtide] is the first listed.
NCT00100984 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00100984 about?
NCT00100984 is a clinical study titled "A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1". The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.
What is the current status of trial NCT00100984?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2004-07-21. Estimated completion is 2005-07-16.
What interventions are being tested in trial NCT00100984?
The interventions under investigation include: FUZEON [enfuvirtide] (DRUG).
Who is sponsoring clinical trial NCT00100984?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00100984's enrollment target sits among peer trials
8 1972nd of 2000 higher than 20 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI